RuiYi Lands $4,000,000 New Financing

  • Feed Type
  • Date
    6/12/2014
  • Company Name
    RuiYi
  • Mailing Address
    505 Coast Blvd S. La Jolla, CA 92037 USA
  • Company Description
    RuiYi is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally.
  • Website
    http://www.ruiyibio.com
  • Transaction Type
    Debt
  • Transaction Amount
    $4,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company’s lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer. RuiYi will also be advancing RYI-018 into preclinical studies. Identified via RuiYi’s iCAPS(TM) platform, RYI-018 is a first-in-class monoclonal antibody to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target.
  • M&A Terms
  • Venture Investor

By posting a comment, you agree to our terms and conditions.